NCT05600140 Viewing Strategy Training in Children With (Cerebral) Visual Impairment
| NCT ID | NCT05600140 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Royal Dutch Visio |
| Condition | Vision Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-10-25 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-10-25 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Viewing strategies are strategies used to process visual Information. Many children with visual impairment seem to lack systematic viewing strategies. However, it is unknown how viewing strategies differ between children with normal vision and children with (cerebral) visual impairment. In addition, viewing strategy training is often adopted in clinical practice, but till date there is no scientific evidence about effectiveness of this approach. The current project has two goals: (1) to measure viewing strategies used by children with normal vision, children with ocular visual impairment and children with CVI, and (2) to evaluate whether training viewing strategies results in more efficiënt visual Information processing.
Eligibility Criteria
Inclusion criteria typically developing children with normal vision: * Age 5-12 years * linear distant visual acuity of 0.1 logMAR or better * Verbal IQ above 70 * Absence of developmental disorders or psychiatric problems like ASS or AD(H)D Inclusion criteria for children with ocular visual impairment: * Age 5-12 years * Children with linear distance visual acuity better \<=1.3logMAR and \>0.1 logMAR * Intact central visual field (at least \> 30 degrees) * Children with a verbal IQ above 70 * Absence of developmental disorders or psychiatric problems like ASS or AD(H)D Inclusion criteria for children with cerebral visual impairment: * Age 5-12 years * Linear distance visual acuity \<=0.3 logMAR * Having the diagnosis CVI (verified by ophthalmologists) * Children with a verbal IQ above 70 * Absence of psychiatric problems like ASS or AD(H)D Additional inclusion criterion for study 2 (evaluating training effectiveness): children with (cerebral) visual impairment should have an indication for viewing strategy training. Training should not be indicated if children have no problems performing academic tasks (i.e. when speed and accuracy of visual processing is within the normal range). The age range for study 2 is 5-9 years. Exclusion criteria: * Children with VI: linear near visual acuity \>1.0 logMAR * Children with visual field defect \< 30 degrees * Children with a verbal IQ below 70 * Children who attended a form of vision training in the past two years * Children with psychiatric problems like ASS or AD(H)D * Auditory impairment or language impairments * Major life events during training
Contact & Investigator
Bianca Huurneman, PhD
PRINCIPAL INVESTIGATOR
Royal Dutch Visio
Frequently Asked Questions
Who can join the NCT05600140 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 12 Years, studying Vision Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05600140 currently recruiting?
Yes, NCT05600140 is actively recruiting participants. Contact the research team at biancahuurneman@visio.org for enrollment information.
Where is the NCT05600140 trial being conducted?
This trial is being conducted at Nijmegen, Netherlands.
Who is sponsoring the NCT05600140 clinical trial?
NCT05600140 is sponsored by Royal Dutch Visio. The principal investigator is Bianca Huurneman, PhD at Royal Dutch Visio. The trial plans to enroll 60 participants.